Jones T - Search Results

1

Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.

Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, Jones T, Price PM, Aboagye EO. Saleem A, et al. Among authors: jones t. Lancet. 2000 Jun 17;355(9221):2125-31. doi: 10.1016/s0140-6736(00)02380-1. Lancet. 2000. PMID: 10902627 Clinical Trial.

2

Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.

Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM. Gupta N, et al. Among authors: jones t. Clin Cancer Res. 2006 May 15;12(10):3115-23. doi: 10.1158/1078-0432.CCR-05-0513. Clin Cancer Res. 2006. PMID: 16707610 Free article. Clinical Trial.

3

Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.

Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM. Harte RJ, et al. Among authors: jones t. J Clin Oncol. 1999 May;17(5):1580-8. doi: 10.1200/JCO.1999.17.5.1580. J Clin Oncol. 1999. PMID: 10334547

4

Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.

Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, Brown GD, Bleehen N, Connors T, Jones T, Price PM, Aboagye EO. Saleem A, et al. Among authors: jones t. J Clin Oncol. 2001 Mar 1;19(5):1421-9. doi: 10.1200/JCO.2001.19.5.1421. J Clin Oncol. 2001. PMID: 11230487 Clinical Trial.

5

In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography.

Aboagye EO, Price PM, Jones T. Aboagye EO, et al. Among authors: jones t. Drug Discov Today. 2001 Mar 1;6(6):293-302. doi: 10.1016/s1359-6446(01)01684-1. Drug Discov Today. 2001. PMID: 11257581

6

Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies.

Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, Brady F, Osman S, Jones T, Price P. Wells P, et al. Among authors: jones t. Cancer Res. 2002 Oct 15;62(20):5698-702. Cancer Res. 2002. PMID: 12384527 Clinical Trial.

7

Metabolic activation of temozolomide measured in vivo using positron emission tomography.

Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P. Saleem A, et al. Among authors: jones t. Cancer Res. 2003 May 15;63(10):2409-15. Cancer Res. 2003. PMID: 12750260

8

Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers.

Wells P, Jones T, Price P. Wells P, et al. Among authors: jones t. Clin Cancer Res. 2003 Dec 15;9(17):6350-6. Clin Cancer Res. 2003. PMID: 14695134

9

2-[11C]thymidine positron emission tomography reproducibility in humans.

Wells P, Gunn RN, Steel C, Ranicar AS, Brady F, Osman S, Jones T, Price P. Wells P, et al. Among authors: jones t. Clin Cancer Res. 2005 Jun 15;11(12):4341-7. doi: 10.1158/1078-0432.CCR-04-1818. Clin Cancer Res. 2005. PMID: 15958616 Free article.

10

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.

Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Anderson HL, et al. Among authors: jones t. J Clin Oncol. 2003 Aug 1;21(15):2823-30. doi: 10.1200/JCO.2003.05.186. Epub 2003 Jun 13. J Clin Oncol. 2003. PMID: 12807935 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,068 results

Search Page

Filters